BOCA RATON, Fla., July 18 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that it will report its 2007 second quarter financial results on Wednesday, August 1, 2007, after market close. The company will host a live webcast at 4:30 p.m. EDT that day to discuss these results.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=100445&eventID=1603855
or via the Nabi Biopharmaceuticals website at http://www.nabi.com.
If you do not have Internet access, the U.S./Canada call-in number is (800) 638-5439, conference code 14030912, and the international call-in number is (617) 614-3945, conference code 14030912. An audio replay will be available for U.S./Canada callers at (888) 286-8010, conference code 74258104, and for international callers at (617) 801-6888, conference code 74258104.
An archived version of the webcast will be available at the same Internet address through August 8, 2007. The audio replay also will be available through August 8, 2007. The press release will be available on the company’s website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has one product on the market today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)]. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram- positive bacterial infections and nicotine addiction. The company has recently announced the formation of the first of two strategic business units: Nabi Biologics. Nabi Biologics has responsibility for the company’s protein and immunological products and development pipeline, including Nabi-HB. The second business unit, Nabi Pharmaceuticals, is expected to be formed later this year and will have responsibility for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs, as well as for the continuing milestone-related clinical development obligations following the sale of PhosLo(R) (calcium acetate). For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.
Nabi Biopharmaceuticals
CONTACT: Investor Relations, +1-561-989-5800
